Ma, Lin
Tao, Xiaohua
Liu, Sujun
Cheng, Hao
Fang, Ruihua
Zhao, Yan
Cha, Amy
Encinas, Gerardo A.
Zhou, Yangmei
Deng, Yujie
Zhang, Jianzhong
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01156-6
Funding for this research was provided by:
This study was sponsored by Pfizer Inc., New York, NY, USA.
Article History
Received: 12 January 2024
Accepted: 3 April 2024
First Online: 15 May 2024
Declarations
:
: Lin Ma, Xiaohua Tao, Hao Cheng, and Jianzhong Zhang have received fees for serving as consultants and speakers for Pfizer Inc. Sujun Liu, Ruihua Fang, and Yan Zhao had no conflict of interest to disclose. Amy Cha, Gerardo A. Encinas, and Yujie Deng are employees and shareholders of Pfizer Inc. Yangmei Zhou is an employee of Pfizer R&D China.
: This analysis of a previously conducted study was exempt from institutional review board approval. All patients or parents/guardians provided written informed consent for participation in the studies. The study was approved by the Quorum Review Institutional Review Board and was conducted in accordance with the ethical principles originating in the Declaration of Helsinki.